Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.69 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.60 |
| ▸ | NMT2 | O60551 | 2/20 | 0.56 |
| ▸ | NMT1 | P30419 | 2/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942368 | 0.96 | SLC6A5 (0.64) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29414633 | 0.94 | SLC6A5 (0.62) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29942202 | 0.94 | SLC6A5 (0.62) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL30340265 | 0.94 | SLC6A5 (0.63) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29675024 | 0.94 | SLC6A5 (0.70) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29429316 | 0.94 | SLC6A5 (0.70) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29429273 | 0.94 | SLC6A5 (0.70) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29429310 | 0.94 | SLC6A5 (0.70) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL8929340 | 0.94 | SLC6A5 (0.77) | SLC6A5NOD1NMT2NMT1TLR2 | |
| SCHEMBL29111716 | 0.94 | SLC6A5 (0.77) | SLC6A5NOD1NMT2NMT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PROTINHI B.V. (NL) | 2025-02-20 | — | — | US | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| WO-2023052636-A1 | PROTEASE INHIBITORS | PROTINHI B.V. (NL) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PREP, DNPEP, TMPRSS15 | SLC6A5 4560/4885NOD1 1493/4885NMT2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.